Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2015 by American British Cowdray Medical Center.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Paul J. Lamothe, American British Cowdray Medical Center Identifier:
First received: May 24, 2013
Last updated: March 13, 2015
Last verified: March 2015
A randomized multicentric parallel arms study involving the use of ketamine for treatment-resistant depression will be held at three national health provider clinics in the Mexican population. The purpose of this study is to determine whether clinical response seen in previous studies is replicable in this population.

Condition Intervention Phase
Depressive Disorder,
Treatment-Resistant Depression
Drug: Ketamine
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population

Resource links provided by NLM:

Further study details as provided by American British Cowdray Medical Center:

Primary Outcome Measures:
  • Changes in baseline HDRS Score [ Time Frame: 20 minutes before and 40 minutes after ketamine infusion. ]
    The Hamilton Depression Rating Scale (HDRS) baseline score will be measured 20 minutes before ketamine infusion. After 40 minutes post-infusion, a second HDRS score will be obtained.

  • Daily change in HDRS post-ketamine infusion. [ Time Frame: 1,2,3,4,5,6 and 7. Days after ketamine infusion ]
    On a daily basis, from day 1-7 post-ketamine infusion, changes in HDRS score will be measured during the daily psychiatric evaluation.

Secondary Outcome Measures:
  • Baseline blood pressure (BP). [ Time Frame: 20 minutes before ketamine infusion. ]
    Baseline BP will be measured during the physical examination 20 minutes before ketamine infusion.

  • Changes from baseline in blood pressure (BP) [ Time Frame: every 5 minutes in a 300 minutes period ]
    BP will be monitored continuously for a 4-hour period. BP assessments will be taken every five minutes for the period mentioned. The assessment will start 20 minutes before ketamine administration and will finish 4hrs after starting.

Estimated Enrollment: 60
Study Start Date: September 2013
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ketamine treated Drug: Ketamine
A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.
Other Name: Ketalar
Placebo Comparator: Control, placebo treated Drug: Placebo
Saline at 0.9% intravenous infusion will be administered over 40 minutes.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age: 18-65 years old
  • Mayor Depressive Disorder Diagnosis based on DSM-IV TR.
  • Classification of MDD as treatment-resistant.
  • No brain structural abnormalities as evidenced by an MRI scan.
  • Signed acceptance of Informed Consent.

Exclusion Criteria:

  • Other psychiatric diagnosis apart from MDD.
  • Substance abuse or dependence (prior or during study).
  • Pregnancy.
  • Congestive heart disease.
  • Personal history of psychosis.
  • First-degree relative with history of psychosis.
  • Glaucoma.
  • Present neurological disease.
  • High blood or pulmonary artery pressure.
  • Declining the signing of the informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01868802

Contact: Paul J Lamothe, M.D. +52 (55) 11031750
Contact: David N Lopez-Garza, M.D. + 52 (55) 11031750

ABC Neurological Center Recruiting
Mexico City, DF, Mexico, 05300
Contact: Eduardo San Esteban, M.D.    +52 (55) 52308000   
Principal Investigator: Paul J Lamothe Molina, M.D.         
Sponsors and Collaborators
Paul J. Lamothe
Principal Investigator: Paul J Lamothe, M.D. American British Cowdray Medical Center
Study Director: David N Lopez-Garza, M.D. American British Cowdray Medical Center
Principal Investigator: Manuel Ruiz-Alvarez, M.D. American British Cowdray Medical Center
  More Information

Responsible Party: Paul J. Lamothe, Chief of the Research Department, Neurological Center., American British Cowdray Medical Center Identifier: NCT01868802     History of Changes
Other Study ID Numbers: ABC KET-DRT-01-2013
Study First Received: May 24, 2013
Last Updated: March 13, 2015

Keywords provided by American British Cowdray Medical Center:
Depressive Disorder

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Treatment-Resistant
Behavioral Symptoms
Mood Disorders
Mental Disorders
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 26, 2017